J
Jee Hyun Kim
Researcher at Seoul National University Bundang Hospital
Publications - 703
Citations - 12600
Jee Hyun Kim is an academic researcher from Seoul National University Bundang Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 46, co-authored 319 publications receiving 9907 citations. Previous affiliations of Jee Hyun Kim include Seoul National University & New Generation University College.
Papers
More filters
Journal ArticleDOI
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer.
Soomin Ahn,Hyun Jeong Kim,Milim Kim,Yul Ri Chung,Eunyoung Kang,Eun Kyu Kim,Se Hyun Kim,Yu Jung Kim,Jee Hyun Kim,In Ah Kim,So Yeon Park +10 more
TL;DR: Positive conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.
Journal ArticleDOI
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
Baek Yeol Ryoo,Ann Li Cheng,Zhenggang Ren,Tae-You Kim,Hongming Pan,Kun Ming Rau,Hye Jin Choi,Joong-Won Park,Jee Hyun Kim,Chia Jui Yen,Ho Yeong Lim,Dongli Zhou,J. Straub,Juergen Scheele,K. Berghoff,Shukui Qin +15 more
TL;DR: In this paper, the highly selective MET inhibitor tepotinib was evaluated in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET overexpression.
Journal ArticleDOI
Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort.
Wan Jeon,Bum Sup Jang,Seung Hyuck Jeon,Jee Hyun Kim,Yu Jung Kim,Se Hyun Kim,Chae-Yong Kim,Jung Ho Han,In Ah Kim +8 more
TL;DR: To evaluate the survival outcomes based on molecular subtypes of breast cancer in patients with brain metastasis, patients withbrain metastasis are treated with or without chemotherapy.
Journal ArticleDOI
Management of the elderly patient with gynecologic cancer: Report of the 2011 workshop in geriatric gynecologic oncology
Dong Hoon Suh,Sokbom Kang,Myong Cheol Lim,Taek Sang Lee,Jeong-Yeol Park,Tae-Joong Kim,Jee Hyun Kim,Kwang Beom Lee,Dong Choon Park,Hyun Hoon Chung,Kidong Kim,Sang Soo Seo,Hak Jae Kim,Mi Kyung Kim,Woong Ju,Jae Weon Kim,Stuart M. Lichtman,Sang Yoon Park +17 more
TL;DR: This paper summarizes what was discussed at the first workshop in geriatric gynecologic oncology and provides evidence-based recommendations for the diagnosis and treatment of Gynecologic cancer in elderly individuals.
Journal ArticleDOI
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Ji-Yeon Kim,Eunjin Lee,Kyunghee Park,Hae Hyun Jung,Woong-Yang Park,Kyung Hun Lee,Joohyuk Sohn,Keun Seok Lee,Kyung Hae Jung,Jee Hyun Kim,Ki Hyeong Lee,Seock-Ah Im,Yeon Hee Park,Yeon Hee Park +13 more
TL;DR: Her2 CN amplification, PIK3CA pathway alteration, and ERBB3 cytoplasmic mutation showed predictive roles on clinical outcomes of HER2‐positive MBC treated with poziotinib.